Assura Plc

DB:75A Stock Report

Market Cap: €1.5b

Assura Valuation

Is 75A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 75A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 75A (€0.46) is trading above our estimate of fair value (€0.25)

Significantly Below Fair Value: 75A is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 75A?

Key metric: As 75A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 75A. This is calculated by dividing 75A's market cap by their current earnings.
What is 75A's PE Ratio?
PE Ratio18.9x
EarningsUK£66.10m
Market CapUK£1.25b

Price to Earnings Ratio vs Peers

How does 75A's PE Ratio compare to its peers?

The above table shows the PE ratio for 75A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.4x
HABA Hamborner REIT
62.7x9.5%€513.3m
LTC LTC Properties
15.3x-2.3%US$1.6b
C2PU Parkway Life Real Estate Investment Trust
25x18.4%S$2.5b
SILA Sila Realty Trust
58.5x10.3%US$1.3b
75A Assura
18.9x19.6%€1.2b

Price-To-Earnings vs Peers: 75A is good value based on its Price-To-Earnings Ratio (18.9x) compared to the peer average (40.4x).

Price to Earnings Ratio vs Industry

How does 75A's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
75A 18.9xIndustry Avg. 25.1xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 75A is good value based on its Price-To-Earnings Ratio (18.9x) compared to the Global Health Care REITs industry average (25x).

Price to Earnings Ratio vs Fair Ratio

What is 75A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

75A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 75A's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 75A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.46
€0.58
+26.1%
8.8%€0.66€0.48n/a9
Dec ’25€0.46
€0.58
+26.8%
8.3%€0.66€0.48n/a9
Nov ’25€0.46
€0.58
+27.0%
6.4%€0.65€0.53n/a9
Oct ’25€0.49
€0.58
+19.2%
6.4%€0.65€0.53n/a9
Sep ’25€0.47
€0.57
+20.6%
5.8%€0.64€0.52n/a9
Aug ’25€0.46
€0.59
+26.9%
5.9%€0.65€0.53n/a9
Jul ’25€0.46
€0.59
+29.1%
5.9%€0.65€0.53n/a9
Jun ’25€0.47
€0.58
+24.0%
5.2%€0.65€0.53n/a10
May ’25€0.47
€0.59
+26.3%
4.0%€0.64€0.56n/a10
Apr ’25€0.47
€0.59
+26.3%
4.0%€0.64€0.56n/a10
Mar ’25€0.51
€0.60
+17.5%
4.3%€0.64€0.56n/a10
Feb ’25€0.50
€0.60
+18.8%
4.8%€0.64€0.56n/a10
Jan ’25€0.54
€0.60
+10.5%
6.3%€0.68€0.55€0.4710
Dec ’24€0.49
€0.60
+21.1%
6.3%€0.68€0.55€0.4610
Nov ’24€0.44
€0.60
+36.0%
7.1%€0.68€0.55€0.4610
Oct ’24€0.46
€0.62
+34.4%
7.4%€0.68€0.55€0.499
Sep ’24€0.51
€0.63
+22.8%
6.5%€0.69€0.57€0.479
Aug ’24€0.53
€0.65
+22.6%
12.7%€0.87€0.57€0.4610
Jul ’24€0.50
€0.69
+37.1%
13.9%€0.88€0.61€0.4610
Jun ’24€0.54
€0.69
+27.9%
13.8%€0.86€0.60€0.4710
May ’24€0.54
€0.69
+28.8%
13.7%€0.85€0.57€0.4710
Apr ’24€0.53
€0.69
+30.9%
13.7%€0.85€0.57€0.4710
Mar ’24€0.56
€0.69
+24.5%
12.8%€0.85€0.57€0.5111
Feb ’24€0.61
€0.72
+17.9%
11.2%€0.85€0.63€0.5011
Jan ’24€0.59
€0.75
+26.8%
11.7%€0.89€0.64€0.5411

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:24
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Assura Plc is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kanad MitraBarclays
Miranda CockburnBerenberg
Tom HorneBerenberg